OGEN
- Oragenics, Inc.
()
Overview
Company Summary
Oragenics, Inc. is a biopharmaceutical company that focuses on the development of innovative therapies for infectious diseases. They specialize in leveraging advanced technology and scientific expertise to create novel solutions for serious medical concerns. The company primarily operates in the field of oral health and infectious diseases, with a particular emphasis on discovering and developing antibiotics against resistant strains of bacteria.
Oragenics is recognized for its proprietary platform known as the "Intelligent Selection and Evolution System" (ISESYNTHESIS�). This platform allows for the rapid, targeted identification and development of potential new therapies. Using this system, Oragenics aims to address the growing concern of antibiotic resistance and develop effective treatments for other infectious diseases.
One of the significant areas of focus for Oragenics is the development of antibiotics to combat drug-resistant bacteria, also known as superbugs. These drug-resistant strains have become a major public health concern worldwide. Oragenics aims to develop novel antibiotics capable of combating these bacteria by targeting specific mechanisms and pathways unique to these pathogens.
In addition to antibiotics, Oragenics has also been involved in the development of therapeutic treatments for oral health issues. One of their notable products in this field is an oral care probiotic known as EvoraPro�, which aims to promote oral health and prevent specific dental issues.
Oragenics strives to employ innovative research and development strategies to create cutting-edge therapies that address significant unmet medical needs. By leveraging its expertise and technological platforms, the company aims to make a positive impact on global health by offering effective solutions for infectious diseases.